PALO ALTO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the release of its inaugural sustainability report which highlights sustainability efforts by the company related to its environmental footprint, contributing positively to society, and improving access ...

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its Chief Executive Officer and President, Jaisim Shah, and Executive Chairman, Henry Ji, Ph.D., will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York, at 4:00 p.m. Eastern ...

The ceremony will be held in celebration of Scilex's launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its ...

销售额情况 - Scilex Holding Company在2024年第一季度ZTlido的毛销售额为3,400万至3,800万美元，同比增长约24%至38%[2] - Scilex Holding Company在2024年第一季度ZTlido的净销售额为1,200万至1,300万美元，同比增长约13%至23%[2]

Investors and Media Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Office: (650) 516-4310 ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year. ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year. Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year. Total product net sales for the quarter e ...

PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly resp ...

"The commercialization of Scilex's three non-opioid products continues on schedule and we anticipate growth to accelerate through this year and beyond 2024. Given our accelerated pace of product growth, we are aggressively implementing our strategy of building out additional logistics and distribution for our commercial products. Signing an additional distribution partner at this point sets the stage for a successful and aggressive product launch into specialized point of care customers. We will continue to ...

PALO ALTO, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research ...

PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a commitment letter (the "Commitment Letter") with Perigrove LLC and Graf Holdings (collectively the "Lender") for a $100 million 5-year term financing with royalty-based paymen ...

In connection with the transaction, upon receipt of the Commitment funds, the Company will issue to the Lender a warrant to purchase up to an aggregate of 32,500,000 shares of the Company's common stock, with an exercise price of $1.20. In the event the Commitment is not funded in accordance with the Commitment Letter, the Deposit will automatically convert to an unsecured loan and the Company will issue an unsecured promissory note (the "Note") to the Lender to evidence such unsecured loan. The Note will h ...